Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The long-term clinical profile observed in these ambrisentan studies is very encouraging.”
MGMichael GerberSVP Clinical Development and Regulatory Affairs, Myogen
“With two positive, well-controlled studies demonstrating robust efficacy and a safety database of more than 400 patients on long-term treatment, we have the foundation for high quality regulatory submissions worldwide.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Ben‐Yehuda et al. (2012) studied this question.